You are here

  • Home
  • Archive
  • Volume 69, Issue 11
  • Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy

Article metrics

Article menu
Download PDFPDF
Original article
Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy

 

Online download statistics by month:

Online download statistics by month: April 2016 to March 2024

AbstractFullPdf
Apr 20162121716
May 20161041610
Jun 20165135
Jul 20161864
Aug 20163558
Sep 201620532
Oct 20164591094
Nov 20164091156
Dec 2016119748
Jan 201714044
Feb 201780127
Mar 201759176
Apr 20174885
May 20173583
Jun 20174765
Jul 20175822
Aug 20177344
Sep 20178284
Oct 20178721
Nov 20179244
Dec 20174632
Jan 20187771
Feb 20184651
Mar 201810131
Apr 20184712
May 20185900
Jun 20187532
Jul 20184832
Aug 20185643
Sep 20183121
Oct 20184700
Nov 20183700
Dec 20184232
Jan 20193432
Feb 20191800
Mar 20192823
Apr 20193732
May 20193242
Jun 20192110
Jul 20192310
Aug 20192500
Sep 20193800
Oct 20192311
Nov 20192102
Dec 20191421
Jan 20202032
Feb 20203110
Mar 20203221
Apr 20203422
May 20204411
Jun 20204400
Jul 20202801
Aug 20201820
Sep 20202200
Oct 20202700
Nov 20203133
Dec 20202811
Jan 20212411
Feb 20211822
Mar 20213511
Apr 20211911
May 20211111
Aug 2021112
Sep 2021111
Oct 20212200
Nov 20213020
Dec 20212910
Jan 20223020
Feb 20221621
Mar 20223110
Apr 20221910
May 20225900
Jun 20224200
Jul 20222643
Aug 20224811
Sep 20225610
Oct 202211540
Nov 20223011
Dec 20221600
Jan 20232522
Feb 20235422
Mar 20231020
Apr 2023400
May 20234110
Jun 2023600
Jul 2023310
Aug 2023911
Sep 2023310
Oct 20232621
Nov 202313300
Dec 20232310
Jan 20241400
Feb 20241200
Mar 20244111
Total4880261351